Kevin learns about the connection between Ps and PsA

GRAPHIC:
[10-SECOND COUNTDOWN BEGINS]

On-screen Text:
SKYRIZI is a prescription medicine used to treat adults with active psoriatic arthritis (PsA).

SAFETY CONSIDERATIONS
SKYRIZI may cause serious side effects, including:

• Serious allergic reactions: Stop using SKYRIZI and get emergency medical help right away if you get any symptoms of a serious allergic reaction.   

• Infections: SKYRIZI may increase your risk of infections. Before starting treatment, your doctor should check you for infections and tuberculosis. Tell your doctor right away if you have an infection or symptoms of one.  

Do not use SKYRIZI if you are allergic to risankizumab-rzaa or any of the ingredients in SKYRIZI.  

Also, tell your doctor if you plan to or recently received a vaccine.  

Please see additional Important Safety Information near the end of this video. Please see full link for the Full Prescribing Information, including the Medication Guide, for SKYRIZI.

GRAPHIC:
Skyrizi® risankizumab-rzaa

On-screen Text:
KEVIN LEARNS ABOUT THE CONNECTION BETWEEN Ps AND PsA

Kevin:
Understanding the connection between psoriasis and psoriatic arthritis is important.

On-screen Text:
KEVIN
SKYRIZI PATIENT WITH ACTIVE PSORIATIC ARTHRITIS AND PLAQUE PSORIASIS

Kevin:
My doctor told me there could be a connection between the psoriatic arthritis inflammation and psoriasis.

On-screen Text:
1 IN 3 PEOPLE WITH PSORIASIS MAY ALSO DEVELOP PSORIATIC ARTHRITIS

Kevin:
I want people to know that even if you have a condition of psoriasis or psoriatic arthritis,... there are things you can do.

On-screen Text:
SKYRIZI LOGO

Kevin:
I was prescribed SKYRIZI after a series of investigating other medicines.

On-screen Text:
LESS JOINT PAIN, STIFFNESS, AND SWELLING

In PsA clinical trials, a majority experienced a 20% improvement in symptoms at week 24.

Kevin:
My joint and skin symptoms improved.

On-screen Text:
90% CLEARER SKIN IN PATIENTS WHO ALSO HAD PLAQUE PSORIASIS

In PsA clinical trials, a majority of those who also had plaque psoriasis saw 90% clearer skin at week 24.

Kevin:
It's important to find a treatment that addresses both skin and joint symptoms.

Kevin:
If someone is diagnosed with psoriatic arthritis, I would encourage them to talk to their [dermatologist]. Research the available treatment options and find the one that’s going to work for you.

V.O./On-Screen Text:
IMPORTANT SAFETY INFORMATION AND USE

SKYRIZI® (risankizumab-rzaa) USE
SKYRIZI is a prescription medicine used to treat adults with active psoriatic arthritis (PsA).

Important Safety Information
What is the most important information I should know about SKYRIZI^® (risankizumab-rzaa)?

SKYRIZI is a prescription medicine that may cause serious side effects, including:

Serious allergic reactions:

• Stop using SKYRIZI and get emergency medical help right away if you get any of the following symptoms of a serious allergic reaction:
• fainting, dizziness, feeling lightheaded (low blood pressure)
• swelling of your face, eyelids, lips, mouth, tongue, or throat
• trouble breathing or throat tightness
• chest tightness
• skin rash, hives
• itching

Infections:
SKYRIZI may lower the ability of your immune system to fight infections and may increase your risk of infections. Your healthcare provider should check you for infections and tuberculosis (TB) before starting treatment with SKYRIZI and may treat you for TB before you begin treatment with SKYRIZI if you have a history of TB or have active TB. Your healthcare provider should watch you closely for signs and symptoms of TB during and after treatment with SKYRIZI. 

• Tell your healthcare provider right away if you have an infection or have symptoms of an infection, including:

• fever, sweats, or chills
• cough
• shortness of breath
• blood in your mucus (phlegm)
• muscle aches
• warm, red, or painful skin or sores on your body different from your psoriasis
• weight loss
• diarrhea or stomach pain
• burning when you urinate or urinating more often than normal

Do not use SKYRIZI if you are allergic to risankizumab-rzaa or any of the ingredients in SKYRIZI. See the Medication Guide or Consumer Brief Summary for a complete list of ingredients. 

Before using SKYRIZI, tell your healthcare provider about all of your medical conditions, including if you:

•  have any of the conditions or symptoms listed in the section “What is the most important information I should know about SKYRIZI?”
• have an infection that does not go away or that keeps coming back. 
• have TB or have been in close contact with someone with TB. 
• have recently received or are scheduled to receive an immunization (vaccine). Medications that interact with the immune system may increase your risk of getting an infection after receiving live vaccines. You should avoid receiving live vaccines right before, during, or right after treatment with SKYRIZI. Tell your healthcare provider that you are taking SKYRIZI before receiving a vaccine.
• are pregnant or plan to become pregnant. It is not known if SKYRIZI can harm your unborn baby. 
• are breastfeeding or plan to breastfeed. It is not known if SKYRIZI passes into your breast milk.
• become pregnant while taking SKYRIZI. You are encouraged to enroll in the Pregnancy Registry, which is used to collect information about the health of you and your baby. Talk to your healthcare provider or call 1-877-302-2161 to enroll in this registry.

Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.

What are the possible side effects of SKYRIZI?

SKYRIZI may cause serious side effects. See “What is the most important information I should know about SKYRIZI?”

The most common side effects of SKYRIZI in people treated for plaque psoriasis and psoriatic arthritis include: upper respiratory infections, headache, feeling tired, injection site reactions, and fungal skin infections.

These are not all the possible side effects of SKYRIZI. Call your doctor for medical advice about side effects.

Use SKYRIZI exactly as your healthcare provider tells you to use it.

SKYRIZI is available in a 150 mg/mL prefilled syringe and pen.

Please see the Full Prescribing Information, including the Medication Guide, for SKYRIZI.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda/gov/medwatch or call 1-800-FDA-1088.

If you are having difficulty paying for your medicine, AbbVie may be able to help. Visit AbbVie.com/PatientAccessSupport to learn more.

© 2024 AbbVie. All rights reserved. SKYRIZI^® and its design are registered trademarks of Abbvie Biotechnology Ltd.